The Analyst and The Gossip Girl read the same public record and disagree on purpose. What is this?
Tracked Companies

Company Dossiers

What the public record suggests each company is trying to do — and the evidence behind the read.

JPMBanks — Diversified

JPMorgan Chase

11 signals2 themes84% confidenceUpdated Oct 14

JPMorgan is running three conversions at once and only one of them shows up in this quarter's headline. The margin book is being repriced rather than grown: full-year net interest income guidance rose to approximately $94.5 billion from $91 billion on net interest income of $25.1 billion, while average loans stayed flat at $1.35 trillion and the 2.61 percent margin gained nine basis points on fixed-rate asset repricing and deposit pricing discipline, with cumulative deposit beta holding near 44 percent and roughly $40 billion of Treasuries maturing within four quarters to reinvest at a premium. Alongside that, the firm is assembling a private credit franchise by renting origination, buying coverage, and lobbying for its capital treatment: a $15 billion forward flow with Blue Owl inside a $50 billion three-year commitment, a plan for 40 private credit professionals announced on LinkedIn, and a $3.6 million quarterly lobbying disclosure whose top two line items are capital rules and private credit funds. The third conversion is the one nobody leads with, an $18 billion technology budget with 40 percent directed at AI and data, more than 200,000 employees on an internal assistant, 2,000 new technical roles, and a $1.5 billion automation benefit that does not yet exist as a quarter. All three are sequenced behind a capital rule that is not final, which is why the bank authorized a $50 billion buyback while describing the pace as calibrated to a re-proposal that could raise its capital requirement by 4 to 8 percent.

PFEDrug Manufacturers — General

Pfizer

11 signals3 themes84% confidenceUpdated Oct 15

Pfizer is converting a pandemic-inflated revenue base into a therapeutic franchise it can grow without the COVID comparison, and it is funding that conversion by dismantling its own cost structure. Third-quarter revenue of $17.2 billion fell 3 percent, but the entire decline is COVID vaccine and antiviral annualization: excluding COVID, revenue grew 8 percent operationally with oncology up 16 percent, full-year guidance held at $61 to $64 billion and $3.05 to $3.25 of adjusted earnings per share, roughly $3.5 billion of COVID inventory was retired with no further write-downs expected, and net debt fell $2.4 billion to $57 billion. The replacement franchise got its most valuable label nine days earlier, when the FDA approved Padcev with Keytruda perioperatively in muscle-invasive bladder cancer, cutting recurrence, progression, or death 42 percent versus observation and adding roughly 18,000 eligible US patients annually. Since then the replacement has changed shape three more times. It is being bought, not only built: Pfizer agreed eight days ago to license a trispecific T-cell engager for up to $4.2 billion, of which $1.9 billion is payable upfront, its chief scientific officer calling it the third external oncology addition of the year while saying the company has been building toward replacement rather than assuming it. The one replacement already far enough along to be tested did not work as designed: a phase 2 combination in advanced breast cancer missed its primary endpoint overall, 71 events against a prespecified 78, and hit it only in a biomarker-defined subgroup covering 41 percent of enrolled patients, in a study that was never powered to establish that subgroup effect and whose phase 3 decision for the first half of 2027 remains undisclosed. Underneath both sits the exclusivity bridge: two generic filers have certified against formulation patents expiring in 2031 and 2032 while the successor program's dosing claims run untouched to 2043. The second replacement is newer and less certain: the Metsera oral GLP-1 produced 11.4 percent mean weight loss at 36 weeks with no plateau, phase 3 begins in the first half of 2027 across three indications, the portfolio now runs under a dedicated business unit with its own governance, and four hours before this snapshot the chief commercial officer declined twice to say whether the launch price will sit at or below the incumbent injectable's list price, saying access rather than cost is the framing and that the decision belongs to the unit's own governance. The money behind all of it comes from a cost program running to $4.3 billion against a $4.0 billion target, with roughly $1.1 billion already reinvested in oncology and obesity, research spending up 8 percent, and a quarterly filing showing cost of sales down 230 basis points, 3,400 positions gone, $612 million still accrued, and six manufacturing sites left to close, two of them disclosed only in the footnote.

New to The Tell? Take a guided tour tailored to your role.